Recent clinical trials have demonstrated the benefits of real-time continuous glucose monitoring (rtCGM) for people with insulin-treated type 2 diabetes (T2D).1–3 Despite these benefits, adoption of rtCGM in the T2D population has been limited by insurance coverage, the lack of awareness of rtCGM in the primary care setting, where the vast majority of people with T2D are treated, and limited access to diabetes care and education specialists.4 New approaches are needed to increase use of rtCGM and advanced technologies for people with T2D. Here, INS is linked to type 2 diabetes mellitus.